Caribou Biosciences is closing its doors. The company could not raise enough money for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma. The shutdown is immediate.
Caribou started in Jennifer Doudna's Berkeley lab. Doudna won the Nobel Prize for her work on genome editing. The company once stood out in the CRISPR field. It pushed two CRISPR-based CAR-T therapies, including vespa-cel for advanced B-cell non-Hodgkin lymphoma. Both are now canceled. In an official company statement on October 6, 2026, Caribou confirmed it was stopping both allogeneic CAR-T programs—vespa-cel for relapsed or refractory B-cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma. The company said it would look for strategic alternatives to get the most value for shareholders.
As of June 30, 2026, Caribou Biosciences reported holding $113.8 million in cash, cash equivalents, and marketable securities.
Over the past year, Caribou worked with the Food and Drug Administration to finalize the design for a Phase 3 vespa-cel trial. RTT News reported that Caribou and the FDA had agreed on the trial design. The study never started. The company could not get the money it needed. CEO Rachel Haurwitz told STAT that without funding, Caribou had to stop all clinical development. There was no way forward.
The cell therapy sector has seen sharp swings. Even strong CRISPR-based projects face tough financial and operational barriers. Caribou blamed the tough funding climate for allogeneic CAR-T therapies. It was too hard to attract new capital. The company started cutting jobs and expenses. Most layoffs will finish in the fourth quarter of 2026, according to Investing.com.
Other companies in the field have shown progress, as reported earlier. But Caribou's story shows how brutal late-stage clinical research can be for smaller firms.
Following the announcement of the program halts, Caribou Biosciences shares dropped approximately 40% in after-hours trading, reflecting the market's immediate reaction to the company's strategic shift.
What this means for CRISPR and cell therapy
Caribou's shutdown is a blunt warning. Scientific pedigree and regulatory progress do not guarantee survival in biotech. The company could not fund a pivotal trial, even with its roots in Doudna's lab and advanced talks with regulators. The cash demands for cell therapy are steep. Only firms with deep pockets or strong partners are likely to get their treatments to patients. Caribou's collapse narrows the road for independent biotech companies trying to bring next-generation cell therapies to market without big outside support.
